European Pharmaceutical Review: Compulsory licenses in Germany

Head of EIP’s Düsseldorf office, Christof Höhne, outlines the implications of Germany’s compulsory licensing in an article for the latest issue of the European Pharmaceutical Review. Two recent, high-profile pharmaceutical cases which have set the course for the future of German IP law are analysed by Christof, who highlights the advantages and disadvantages faced by both parties in a licensing negotiation.

The article can be read on the European Pharmaceutical Review website here.

EIP strengthens patent litigation team with appointment of fifth London Partner

EIP today announces the appointment of Kathleen Fox Murphy as Partner to the patent litigation group. Kathleen joins from Browne Jacobson, where she held the role of Partner and Head of the London Patent Litigation Team for three years. Kathleen previ...

EIP join CIPA / CITMA Brexit USA Roadshows

EIP took part in a series of events held across the US organised by CIPA and CITMA - “IP Beyond Brexit”. Matt Maitland was on a panel discussion focused on “Trademark and Design aspects of Brexit” at events held in Washington on 22 April and Boston on ...

Why confidentiality may not be enough to safeguard your US patent prospects

In Helsinn Healthcare S.A. et al. v. Teva Pharmaceuticals USA, Inc., No. 17-1229, the US Supreme Court held that the assessment of whether an invention had been put “on sale”, and had therefore entered the prior art, was the same under the America Inve...

EIP named Patent Contentious Firm of the Year for second time

EIP has won the coveted UK Patent Contentious Firm of the Year award from Managing Intellectual Property Magazine for the second year in a row. The award was presented at the influential MIP Awards 2019 ceremony in London last night. Led by Gary Moss,...

European Pharmaceutical Review: Compulsory licenses in Germany

Our cookies

Essential

Analytics

Social media & third party